Centinel Spine completed the acquisition of the worldwide prodisc® total disc replacement assets from DePuy Synthes Products.
The portfolio includes prodisc C and prodisc L in the U.S., and prodisc VIVO, prodisc NOVA, prodisc C, prodisc L and prodisc O plus the DISCOVER™ Cervical device to market ex-U.S.
Viscogliosi Brothers, LLC, a lead investor in Centinel Spine, was the founder of Spine Solutions, the company that led the original Investigational Device Exemption study to bring prodisc to the U.S.
The transaction supports Centinel’s ex-U.S. expansion beyond its focus on the U.S. and Australian markets. When the transaction was first announced in September 2017, Mr. John Viscogliosi, Chairman & Chief Executive Officer of Centinel Spine, told ORTHOWORLD that prodisc C and prodisc L are the only assets in the purchase with premarket approval in the U.S. Centinel intends to initiate U.S. clinical studies to secure approval for other products in the portfolio.
Centinel Spine completed the acquisition of the worldwide prodisc® total disc replacement assets from DePuy Synthes Products.
The portfolio includes prodisc C and prodisc L in the U.S., and prodisc VIVO, prodisc NOVA, prodisc C, prodisc L and prodisc O plus the DISCOVER™ Cervical device to market...
Centinel Spine completed the acquisition of the worldwide prodisc® total disc replacement assets from DePuy Synthes Products.
The portfolio includes prodisc C and prodisc L in the U.S., and prodisc VIVO, prodisc NOVA, prodisc C, prodisc L and prodisc O plus the DISCOVER™ Cervical device to market ex-U.S.
Viscogliosi Brothers, LLC, a lead investor in Centinel Spine, was the founder of Spine Solutions, the company that led the original Investigational Device Exemption study to bring prodisc to the U.S.
The transaction supports Centinel’s ex-U.S. expansion beyond its focus on the U.S. and Australian markets. When the transaction was first announced in September 2017, Mr. John Viscogliosi, Chairman & Chief Executive Officer of Centinel Spine, told ORTHOWORLD that prodisc C and prodisc L are the only assets in the purchase with premarket approval in the U.S. Centinel intends to initiate U.S. clinical studies to secure approval for other products in the portfolio.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
